Fate Therapeutics, Inc.
NASDAQ:FATE
2.55 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 63.533 | 96.3 | 55.846 | 31.434 | 10.68 | 4.74 | 4.106 | 4.402 | 2.431 | 0 | 0.971 | 2.67 | 1.17 |
| Cost of Revenue
| 18.282 | 13.758 | 5.85 | 125.623 | 87.77 | 56.024 | 34.358 | 26.452 | 19.861 | 16.435 | 12.007 | 11.999 | 0 |
| Gross Profit
| 45.251 | 82.542 | 49.996 | -94.189 | -77.09 | -51.284 | -30.252 | -22.05 | -17.43 | -16.435 | -11.036 | -9.329 | 1.17 |
| Gross Profit Ratio
| 0.712 | 0.857 | 0.895 | -2.996 | -7.218 | -10.819 | -7.368 | -5.009 | -7.17 | 0 | -11.366 | -3.494 | 1 |
| Reseach & Development Expenses
| 143.414 | 320.454 | 215.519 | 125.623 | 87.77 | 56.024 | 34.358 | 26.452 | 19.861 | 16.435 | 12.007 | 11.999 | 9.858 |
| General & Administrative Expenses
| 81.448 | 84.232 | 57.321 | 33.896 | 23.637 | 15.808 | 11.873 | 9.913 | 10.352 | 8.469 | 6.639 | 4.228 | 4.605 |
| Selling & Marketing Expenses
| -2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 79.448 | 84.232 | 57.321 | 33.896 | 23.637 | 15.808 | 11.873 | 9.913 | 10.352 | 8.469 | 6.639 | 4.228 | 4.605 |
| Other Expenses
| 9.882 | 20.823 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 222.862 | 404.686 | 272.84 | 159.519 | 111.407 | 71.832 | 46.231 | 36.365 | 30.213 | 24.904 | 18.646 | 16.227 | 14.463 |
| Operating Income
| -177.611 | -308.386 | -216.994 | -128.085 | -100.727 | -67.092 | -42.125 | -31.963 | -27.782 | -24.904 | -17.675 | -13.557 | -13.293 |
| Operating Income Ratio
| -2.796 | -3.202 | -3.886 | -4.075 | -9.431 | -14.154 | -10.259 | -7.261 | -11.428 | 0 | -18.203 | -5.078 | -11.362 |
| Total Other Income Expenses Net
| 16.683 | 26.665 | 4.843 | -45.302 | 2.578 | 0.494 | -0.118 | -1.499 | -2.21 | -0.432 | -2.429 | -0.196 | -0.009 |
| Income Before Tax
| -160.928 | -281.721 | -212.151 | -173.387 | -98.149 | -66.598 | -42.952 | -33.462 | -29.992 | -25.883 | -20.894 | -14.239 | -13.427 |
| Income Before Tax Ratio
| -2.533 | -2.925 | -3.799 | -5.516 | -9.19 | -14.05 | -10.461 | -7.602 | -12.337 | 0 | -21.518 | -5.333 | -11.476 |
| Income Tax Expense
| 18.114 | -26.665 | -5.85 | -3.087 | -0.441 | 2.19 | 0.297 | -0.743 | -0.677 | 0.053 | 0.796 | 0.487 | 0.127 |
| Net Income
| -160.928 | -255.056 | -206.301 | -170.3 | -97.708 | -66.598 | -42.952 | -33.462 | -29.992 | -25.883 | -20.894 | -14.239 | -13.427 |
| Net Income Ratio
| -2.533 | -2.649 | -3.694 | -5.418 | -9.149 | -14.05 | -10.461 | -7.602 | -12.337 | 0 | -21.518 | -5.333 | -11.476 |
| EPS
| -1.64 | -2.63 | -2.18 | -2.07 | -1.43 | -1.19 | -1.02 | -1.05 | -1.18 | -1.27 | -3.54 | -1.61 | -1.51 |
| EPS Diluted
| -1.64 | -2.63 | -2.18 | -2.07 | -1.43 | -1.19 | -1.02 | -1.05 | -1.18 | -1.27 | -3.54 | -1.61 | -1.51 |
| EBITDA
| -159.329 | -308.386 | -215.685 | -125.685 | -96.397 | -64.902 | -41.566 | -31.825 | -27.772 | -24.902 | -17.098 | -12.966 | -12.619 |
| EBITDA Ratio
| -2.508 | -3.202 | -3.862 | -3.998 | -9.026 | -13.692 | -10.123 | -7.23 | -11.424 | 0 | -17.609 | -4.856 | -10.785 |